Clarkston Shares Guest Column on CGT Manufacturing for Commercialization
July 13, 2026 | Clarkston Consulting’s Lynette Nazabal and Riley Welch recently shared a guest column with Cell & Gene on CGT manufacturing for commercialization. Read an excerpt below and the full article here.
Building CGT Manufacturing Capacity For The Next Commercial Era
“For CGT companies, the challenge is not only securing manufacturing capacity for clinical development today but also building a path to commercial-scale production and sustained regulatory compliance. In response, contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) are investing in capacity, automation, and standardized platform processes to support CGT developers more effectively. These investments are designed to improve throughput and accelerate release timelines while maintaining quality controls and allowing facilities to adapt as client pipelines evolve. In this piece, we take a look at several recent investments — mostly by CDMOs and CMOs, though not solely — that are expanding manufacturing capacity to support the growing cell and gene therapy pipeline, associated technology and platform trends, and the impacts on CGT manufacturing from key M&As and geopolitical factors.”
Also read on: outsourcedpharma.com